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Background:  Drug eluting stents (DES) are faced with clinical problems (late malapposition, late thrombosis) that may be due to persisting 
coating polymer presence in the late phase after implantation. We hypothesized that a bioabsorbable (BAO), fish-oil, omega3 fatty acid coating 
containing ISA 247, a cyclosporin analogue, that is resorbed by the vascular wall within 30 days after implantation, would reduce early and late 
complications after coronary stenting.
Methods:  Patients with stable coronary artery disease were included. Major entrance criteria were lesions smaller than 14 mm, treatable with a 
3.0/16 mm stent. Patients were in a blinded fashion randomized between the bare metal stent (exactly the same outlook as the carrier of the BAO 
coated stent). Primary end point was in-stent and in-segment luminal late loss. Secondary endpoints were safety at 30 days and 6 months
Results:  100 patients were randomized. 49 received the bare metal stent (BMS), 51 were implanted with the BAO ISA 247 stent. All patients 
received a control angiogram at 6 months. Device success was 98% in both groups.Late loss at 6 months was 0.71 +/- 0.47 vs. 0.79 +/- 0.53 (NS) 
respectively. Diameter stenosis was 32 +/- 17 vs 37 +/- 18 (NS). Binary restenosis rate was 14 vs 20% (NS). Stent thrombosis was zero in both 
groups, MACE at 6 months 22 vs 29 % (NS).
Conclusions:  Although the bare metal stent revealed an excellent performance, no additional benefit was seen from a bioabsorbable fish oil 
coating containing ISA 247, a cyclosporin analogue. The safety profile however was excellent, and therefore merits other trials with more potent 
drugs.
